Press Release

Verkkokauppa.com Oyj STOCK EXCHANGE RELEASE        6 May 2024 at 2.00 p.m. EEST

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.

Company reports EPS of $4.14, Economic EPS of $5.37 in first quarter

Conference call and webcast scheduled for May 6, 2024, at 8:00 a.m. EDT (2:00 p.m. CEST)

Company Updates 2024 Outlook; Raises Adjusted EBITDA Guidance
Net Sales Driven by Volume-Based Growth 
Profitability Improvement Driven by Lower Input, Quality and Logistics Costs

WAYNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 14, 2024, to shareholders of record at the close of business on May 15, 2024. Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

On 7 February 2024, Pandora announced a new share buyback programme, cf. Company announcement no. 843. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
                                                                                                                                                      
The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes.

Verkkokauppa.com Oyj: Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act; Samuli Seppälä’s holding in Verkkokauppa.com

Verkkokauppa.com Oyj - Managers' Transactions – Seppälä

SINGAPORE and SHANGHAI, China, May 06, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”) a key player in the global hotel industry, today announced that it will schedule to release its unaudited financial results for the first quarter of 2024 on Friday, May 17, 2024 (Hong Kong time), after the trading hours of The Stock Exchange of Hong Kong Limited and before the opening of the U.S. market.

ZYNLONTA^® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)¹ compared to 1Q 2023

Raison sociale de l’émetteur : Crédit Agricole S.A. – SA au capital de 9 077 707 050 euros
Immatriculée sous le n° 784 608 416 R.C.S. NANTERRE
Siège social : MONTROUGE (92120) 12, place des Etats-Unis

New Partnership Expands USI’s Texas-Based Presence and Expertise

PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024.

Ilkka Oyj                Osavuosikatsaus 6.5.2024, klo 13.00

ILKKA-KONSERNIN OSAVUOSIKATSAUS 1.1.-31.3.2024

TAMMI-MAALISKUU 2024
- Liikevaihto 13 451 tuhatta euroa (14 187 tuhatta euroa)
- Oikaistu oman toiminnan liiketappio 133 tuhatta euroa (oikaistu oman toiminnan liiketappio 22 tuhatta euroa), -1,0 prosenttia (-0,2 %) liikevaihdosta
- Liiketappio 608 tuhatta euroa (liiketappio 629 tuhatta euroa), -4,5 prosenttia (-4,4 %) liikevaihdosta
- Nettorahoituserät olivat 1 447 tuhatta euroa (700 tuhatta euroa).
- Voitto ennen veroja 839 tuhatta euroa (70 tuhatta euroa) ja katsauskauden tulos 557 tuhatta euroa (-72 tuhatta euroa).
- Tulos/ osake 0,02 euroa (-0,00 euroa)
- Yhtiön rahoitusasema on vahva, omavaraisuusaste 87,7 % (86,2 %) ja nettovelkaantumisaste -27,5 % (-27,9 %)

AVAINLUVUT